Australia's most trusted
source of pharma news
Posted 7 October 2025 AM
One new brand and two new forms of previously approved medicines have hit the ARTG, with the sponsors already on the agenda for the PBAC's November meeting.
Roche has a new form of 5q spinal muscular atrophy drug Evrysdi approved, as a tablet. It's currently listed as a powder for oral solution, and the tablet form adds convenience some people may desire, such as being able to be stored at room temperature instead of refrigerated. It can be taken whole or mixed with non-chlorinated water.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.